Published in Antimicrob Agents Chemother on August 01, 2005
Regional Isolation Drives Bacterial Diversification within Cystic Fibrosis Lungs. Cell Host Microbe (2015) 2.98
Growth phenotypes of Pseudomonas aeruginosa lasR mutants adapted to the airways of cystic fibrosis patients. Mol Microbiol (2007) 2.87
Pseudomonas aeruginosa: resistance to the max. Front Microbiol (2011) 2.76
Emergence of epidemic multidrug-resistant Enterococcus faecium from animal and commensal strains. MBio (2013) 2.20
Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa isolates from Spanish hospitals. Antimicrob Agents Chemother (2007) 2.04
The role of natural environments in the evolution of resistance traits in pathogenic bacteria. Proc Biol Sci (2009) 1.94
Evolutionary origins of invasive populations. Evol Appl (2008) 1.73
Genetic adaptation of Pseudomonas aeruginosa to the airways of cystic fibrosis patients is catalyzed by hypermutation. J Bacteriol (2008) 1.63
Resistance mechanisms of multiresistant Pseudomonas aeruginosa strains from Germany and correlation with hypermutation. Antimicrob Agents Chemother (2007) 1.63
An analogy between the evolution of drug resistance in bacterial communities and malignant tissues. Nat Rev Cancer (2011) 1.58
Widespread pyocyanin over-production among isolates of a cystic fibrosis epidemic strain. BMC Microbiol (2007) 1.43
Ecology and evolution as targets: the need for novel eco-evo drugs and strategies to fight antibiotic resistance. Antimicrob Agents Chemother (2011) 1.40
The thymidine-dependent small-colony-variant phenotype is associated with hypermutability and antibiotic resistance in clinical Staphylococcus aureus isolates. Antimicrob Agents Chemother (2008) 1.26
Efficacy and potential for resistance selection of antipseudomonal treatments in a mouse model of lung infection by hypermutable Pseudomonas aeruginosa. Antimicrob Agents Chemother (2006) 1.22
A quorum sensing regulated small volatile molecule reduces acute virulence and promotes chronic infection phenotypes. PLoS Pathog (2011) 1.13
Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. Antimicrob Agents Chemother (2009) 1.13
Coculture of Staphylococcus aureus with Pseudomonas aeruginosa Drives S. aureus towards Fermentative Metabolism and Reduced Viability in a Cystic Fibrosis Model. J Bacteriol (2015) 1.13
Coexistence and within-host evolution of diversified lineages of hypermutable Pseudomonas aeruginosa in long-term cystic fibrosis infections. PLoS Genet (2014) 1.12
Inactivation of the mismatch repair system in Pseudomonas aeruginosa attenuates virulence but favors persistence of oropharyngeal colonization in cystic fibrosis mice. J Bacteriol (2007) 1.12
Mucoidy, quorum sensing, mismatch repair and antibiotic resistance in Pseudomonas aeruginosa from cystic fibrosis chronic airways infections. PLoS One (2010) 1.11
Role of mutation in Pseudomonas aeruginosa biofilm development. PLoS One (2009) 1.11
Environmental stress and antibiotic resistance in food-related pathogens. Appl Environ Microbiol (2006) 1.11
The glycerol-3-phosphate permease GlpT is the only fosfomycin transporter in Pseudomonas aeruginosa. J Bacteriol (2009) 1.09
Pseudomonas aeruginosa Diversification during Infection Development in Cystic Fibrosis Lungs-A Review. Pathogens (2014) 1.05
Influence of high mutation rates on the mechanisms and dynamics of in vitro and in vivo resistance development to single or combined antipseudomonal agents. Antimicrob Agents Chemother (2007) 1.04
Antibiotic resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system. Antimicrob Agents Chemother (2009) 1.02
Adaptation of iron homeostasis pathways by a Pseudomonas aeruginosa pyoverdine mutant in the cystic fibrosis lung. J Bacteriol (2014) 1.02
Association between hypermutator phenotype, clinical variables, mucoid phenotype, and antimicrobial resistance in Pseudomonas aeruginosa. J Clin Microbiol (2008) 1.01
Clonal dissemination, emergence of mutator lineages and antibiotic resistance evolution in Pseudomonas aeruginosa cystic fibrosis chronic lung infection. PLoS One (2013) 0.96
Assessing the emergence of resistance: the absence of biological cost in vivo may compromise fosfomycin treatments for P. aeruginosa infections. PLoS One (2010) 0.95
The Pseudomonas aeruginosa pfpI gene plays an antimutator role and provides general stress protection. J Bacteriol (2008) 0.95
Optimization of Polymyxin B in Combination with Doripenem To Combat Mutator Pseudomonas aeruginosa. Antimicrob Agents Chemother (2016) 0.93
Enhanced membrane disruption and antibiotic action against pathogenic bacteria by designed histidine-rich peptides at acidic pH. Antimicrob Agents Chemother (2006) 0.92
Genotypic and phenotypic variation in Pseudomonas aeruginosa reveals signatures of secondary infection and mutator activity in certain cystic fibrosis patients with chronic lung infections. Infect Immun (2011) 0.92
Epistatic roles for Pseudomonas aeruginosa MutS and DinB (DNA Pol IV) in coping with reactive oxygen species-induced DNA damage. PLoS One (2011) 0.91
Megacities as sources for pathogenic bacteria in rivers and their fate downstream. Int J Microbiol (2010) 0.90
Dynamics of mutator and antibiotic-resistant populations in a pharmacokinetic/pharmacodynamic model of Pseudomonas aeruginosa biofilm treatment. Antimicrob Agents Chemother (2011) 0.90
The GO system prevents ROS-induced mutagenesis and killing in Pseudomonas aeruginosa. FEMS Microbiol Lett (2009) 0.89
Evolution and adaptation in Pseudomonas aeruginosa biofilms driven by mismatch repair system-deficient mutators. PLoS One (2011) 0.87
Effect of ciprofloxacin concentration on the frequency and nature of resistant mutants selected from Pseudomonas aeruginosa mutS and mutT hypermutators. Antimicrob Agents Chemother (2011) 0.86
Development of resistance in wild-type and hypermutable Pseudomonas aeruginosa strains exposed to clinical pharmacokinetic profiles of meropenem and ceftazidime simulated in vitro. Antimicrob Agents Chemother (2007) 0.86
Frequency of spontaneous resistance to fosfomycin combined with different antibiotics in Pseudomonas aeruginosa. Antimicrob Agents Chemother (2010) 0.86
Bioengineered lysozyme reduces bacterial burden and inflammation in a murine model of mucoid Pseudomonas aeruginosa lung infection. Antimicrob Agents Chemother (2013) 0.84
A trade-off between oxidative stress resistance and DNA repair plays a role in the evolution of elevated mutation rates in bacteria. Proc Biol Sci (2013) 0.84
Lytic phages obscure the cost of antibiotic resistance in Escherichia coli. ISME J (2015) 0.84
Extensively drug-resistant Pseudomonas aeruginosa: risk of bloodstream infection in hospitalized patients. Eur J Clin Microbiol Infect Dis (2012) 0.84
The complex interplay of iron, biofilm formation, and mucoidy affecting antimicrobial resistance of Pseudomonas aeruginosa. Pathog Dis (2014) 0.82
Expression and antimicrobial function of bactericidal permeability-increasing protein in cystic fibrosis patients. Infect Immun (2006) 0.81
Fighting microbial drug resistance: a primer on the role of evolutionary biology in public health. Evol Appl (2015) 0.80
Development of genomic resources for a thraustochytrid pathogen and investigation of temperature influences on gene expression. PLoS One (2013) 0.79
Emergence of polymyxin B resistance influences pathogenicity in Pseudomonas aeruginosa mutators. Antimicrob Agents Chemother (2015) 0.79
Pharmacokinetics and pharmacodynamics of aerosolized antibacterial agents in chronically infected cystic fibrosis patients. Clin Microbiol Rev (2014) 0.79
Ecological and temporal constraints in the evolution of bacterial genomes. Genes (Basel) (2011) 0.78
Resistance suppression by high-intensity, short-duration aminoglycoside exposure against hypermutable and non-hypermutable Pseudomonas aeruginosa. J Antimicrob Chemother (2016) 0.78
Induction of mycobacterial resistance to quinolone class antimicrobials. Antimicrob Agents Chemother (2012) 0.77
Evidence of inhaled tobramycin in non-cystic fibrosis bronchiectasis. Open Respir Med J (2015) 0.77
Genotypic and phenotypic analyses of a Pseudomonas aeruginosa chronic bronchiectasis isolate reveal differences from cystic fibrosis and laboratory strains. BMC Genomics (2015) 0.76
Increased susceptibility to colistin in hypermutable Pseudomonas aeruginosa strains from chronic respiratory infections. Antimicrob Agents Chemother (2007) 0.75
Hypermutable Pseudomonas aeruginosa in Cystic fibrosis patients from two Brazilian cities. J Clin Microbiol (2013) 0.75
Sequential Treatment of Biofilms with Aztreonam and Tobramycin Is a Novel Strategy for Combating Pseudomonas aeruginosa Chronic Respiratory Infections. Antimicrob Agents Chemother (2016) 0.75
Acinetobacter baumannii Repeatedly Evolves a Hypermutator Phenotype in Response to Tigecycline That Effectively Surveys Evolutionary Trajectories to Resistance. PLoS One (2015) 0.75
A non-canonical mismatch repair pathway in prokaryotes. Nat Commun (2017) 0.75
Involvement of stress-related genes polB and PA14_46880 in biofilm formation of Pseudomonas aeruginosa. Infect Immun (2014) 0.75
Chronic respiratory infections by mucoid carbapenemase-producing Pseudomonas aeruginosa strains, a new potential public health problem. Antimicrob Agents Chemother (2008) 0.75
A Population Genomics Approach to Assessing the Genetic Basis of Within-Host Microevolution Underlying Recurrent Cryptococcal Meningitis Infection. G3 (Bethesda) (2017) 0.75
Co-existence of multidrug-resistant and -susceptible strains of Pseudomonas aeruginosa from a single clinical isolate. Curr Microbiol (2009) 0.75
Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol (1995) 88.05
Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen. Nature (2000) 32.30
Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J (2004) 16.84
Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia. Microbiol Rev (1996) 13.91
High mutation frequencies among Escherichia coli and Salmonella pathogens. Science (1996) 10.88
Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med (2003) 9.78
Lung infections associated with cystic fibrosis. Clin Microbiol Rev (2002) 9.20
High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. Science (2000) 9.14
Evolution of high mutation rates in experimental populations of E. coli. Nature (1997) 8.68
Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin Infect Dis (2002) 6.76
Role of mutator alleles in adaptive evolution. Nature (1997) 5.95
Transformation of Pseudomonas aeruginosa by electroporation. Nucleic Acids Res (1989) 4.75
Nosocomial infections in adult intensive-care units. Lancet (2003) 3.86
Costs and benefits of high mutation rates: adaptive evolution of bacteria in the mouse gut. Science (2001) 3.76
Highly variable mutation rates in commensal and pathogenic Escherichia coli. Science (1997) 3.67
Efficacy of aerosolized tobramycin in patients with cystic fibrosis. N Engl J Med (1993) 3.27
Computed tomography of bronchiectasis. J Comput Assist Tomogr (1982) 3.01
Association between airway bacterial load and markers of airway inflammation in patients with stable chronic bronchitis. Am J Med (2000) 3.00
Spontaneous mutators in bacteria: insights into pathways of mutagenesis and repair. Annu Rev Microbiol (1996) 2.79
Epidemiology of chronic Pseudomonas aeruginosa infections in cystic fibrosis. J Infect Dis (1994) 2.64
Effect of inhaled tobramycin on early Pseudomonas aeruginosa colonisation in patients with cystic fibrosis. Lancet (2001) 2.51
Clinical, pathophysiologic, and microbiologic characterization of bronchiectasis in an aging cohort. Chest (1995) 2.43
The mismatch repair system (mutS, mutL and uvrD genes) in Pseudomonas aeruginosa: molecular characterization of naturally occurring mutants. Mol Microbiol (2002) 2.28
Small-colony variants of Pseudomonas aeruginosa in cystic fibrosis. Clin Infect Dis (1999) 2.18
Escherichia coli mutator genes. Trends Microbiol (1999) 2.11
The role of mutators in the emergence of antibiotic-resistant bacteria. Drug Resist Updat (2003) 2.07
Pulsed-field gel electrophoresis. Methods Mol Med (1998) 1.94
High rate of macrolide resistance in Staphylococcus aureus strains from patients with cystic fibrosis reveals high proportions of hypermutable strains. J Infect Dis (2003) 1.84
Mutator clones of Neisseria meningitidis in epidemic serogroup A disease. Proc Natl Acad Sci U S A (2002) 1.77
Development of resistance during antimicrobial therapy: a review of antibiotic classes and patient characteristics in 173 studies. Pharmacotherapy (1995) 1.72
Lung function in bronchiectasis: the influence of Pseudomonas aeruginosa. Eur Respir J (1996) 1.68
Hypermutation and the preexistence of antibiotic-resistant Pseudomonas aeruginosa mutants: implications for susceptibility testing and treatment of chronic infections. Antimicrob Agents Chemother (2004) 1.67
Hypermutation as a factor contributing to the acquisition of antimicrobial resistance. Clin Infect Dis (2003) 1.58
Effect of sputum bacteriology on the quality of life of patients with bronchiectasis. Eur Respir J (1997) 1.36
Antimicrobial susceptibility of Pseudomonas aeruginosa: results of a UK survey and evaluation of the British Society for Antimicrobial Chemotherapy disc susceptibility test. J Antimicrob Chemother (2001) 1.32
Bronchiectasis: comparison of preoperative thin-section CT and pathologic findings in resected specimens. Radiology (1995) 1.30
Pseudomonal infections in patients with COPD: epidemiology and management. Am J Respir Med (2003) 1.26
Dynamics of long-term colonization of respiratory tract by Haemophilus influenzae in cystic fibrosis patients shows a marked increase in hypermutable strains. J Clin Microbiol (2004) 1.25
Lack of association between hypermutation and antibiotic resistance development in Pseudomonas aeruginosa isolates from intensive care unit patients. Antimicrob Agents Chemother (2004) 1.18
Detection and susceptibility testing of hypermutable Pseudomonas aeruginosa strains with the Etest and disk diffusion. Antimicrob Agents Chemother (2004) 1.15
Emergence of phenotypic variants upon mismatch repair disruption in Pseudomonas aeruginosa. Microbiology (2004) 1.10
Role of chronic Pseudomonas aeruginosa infection in the development of bronchiectasis. Chest (1992) 1.09
Genome macrorestriction analysis of sequential Pseudomonas aeruginosa isolates from bronchiectasis patients without cystic fibrosis. J Clin Microbiol (1996) 1.02
Epidemiological analysis of sequential Pseudomonas aeruginosa isolates from chronic bronchiectasis patients without cystic fibrosis. J Clin Microbiol (1999) 0.92
Genes encoding TEM-4, SHV-2, and CTX-M-10 extended-spectrum beta-lactamases are carried by multiple Klebsiella pneumoniae clones in a single hospital (Madrid, 1989 to 2000). Antimicrob Agents Chemother (2002) 3.23
Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Arch Intern Med (2008) 3.23
Identification and prospective validation of clinically relevant chronic obstructive pulmonary disease (COPD) subtypes. Thorax (2010) 3.06
Community-onset bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: risk factors and prognosis. Clin Infect Dis (2010) 2.76
Anti-tissue antibodies are related to lung function in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2010) 2.45
Chronic Pseudomonas aeruginosa infection in chronic obstructive pulmonary disease. Clin Infect Dis (2008) 2.27
Coevolution with viruses drives the evolution of bacterial mutation rates. Nature (2007) 2.23
Beta-lactam resistance response triggered by inactivation of a nonessential penicillin-binding protein. PLoS Pathog (2009) 2.20
A randomized trial of intravenous glutamine supplementation in trauma ICU patients. Intensive Care Med (2014) 2.19
Stepwise upregulation of the Pseudomonas aeruginosa chromosomal cephalosporinase conferring high-level beta-lactam resistance involves three AmpD homologues. Antimicrob Agents Chemother (2006) 2.16
Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients. Antimicrob Agents Chemother (2010) 2.16
Epidemiology of extended-spectrum beta-lactamase-producing Enterobacter isolates in a Spanish hospital during a 12-year period. J Clin Microbiol (2002) 2.04
Skeletal muscle apoptosis and weight loss in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2002) 2.01
Molecular mechanisms of beta-lactam resistance mediated by AmpC hyperproduction in Pseudomonas aeruginosa clinical strains. Antimicrob Agents Chemother (2005) 1.97
Molecular analysis of the contribution of the capsular polysaccharide and the lipopolysaccharide O side chain to the virulence of Klebsiella pneumoniae in a murine model of pneumonia. Infect Immun (2002) 1.88
Role of changes in the L3 loop of the active site in the evolution of enzymatic activity of VIM-type metallo-beta-lactamases. J Antimicrob Chemother (2010) 1.81
Extended-spectrum beta-lactamase-producing Escherichia coli in Spain belong to a large variety of multilocus sequence typing types, including ST10 complex/A, ST23 complex/A and ST131/B2. Int J Antimicrob Agents (2009) 1.74
Characterization of a large outbreak by CTX-M-1-producing Klebsiella pneumoniae and mechanisms leading to in vivo carbapenem resistance development. J Clin Microbiol (2006) 1.73
Consensus document on the overlap phenotype COPD-asthma in COPD. Arch Bronconeumol (2012) 1.68
Genetic markers of widespread extensively drug-resistant Pseudomonas aeruginosa high-risk clones. Antimicrob Agents Chemother (2012) 1.56
Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains. Antimicrob Agents Chemother (2009) 1.55
Overexpression of AmpC and efflux pumps in Pseudomonas aeruginosa isolates from bloodstream infections: prevalence and impact on resistance in a Spanish multicenter study. Antimicrob Agents Chemother (2011) 1.54
Characterization of plasmids encoding blaESBL and surrounding genes in Spanish clinical isolates of Escherichia coli and Klebsiella pneumoniae. J Antimicrob Chemother (2008) 1.53
Effect of adequate single-drug vs combination antimicrobial therapy on mortality in Pseudomonas aeruginosa bloodstream infections: a post Hoc analysis of a prospective cohort. Clin Infect Dis (2013) 1.52
Metallo-beta-lactamase-producing Pseudomonas putida as a reservoir of multidrug resistance elements that can be transferred to successful Pseudomonas aeruginosa clones. J Antimicrob Chemother (2010) 1.50
[Molecular characterization of a glycopeptide-resistant Enterococcus faecalis outbreak in an intensive care unit]. Enferm Infecc Microbiol Clin (2005) 1.44
Nosocomial spread of colistin-only-sensitive sequence type 235 Pseudomonas aeruginosa isolates producing the extended-spectrum beta-lactamases GES-1 and GES-5 in Spain. Antimicrob Agents Chemother (2009) 1.44
[Characterization and molecular epidemiology of ESBL in Escherichia coli and Klebsiella pneumoniae in 11 Spanish hospitals (2004)]. Enferm Infecc Microbiol Clin (2008) 1.43
Benefit of having multiple ampD genes for acquiring beta-lactam resistance without losing fitness and virulence in Pseudomonas aeruginosa. Antimicrob Agents Chemother (2008) 1.42
PBP3 inhibition elicits adaptive responses in Pseudomonas aeruginosa. Mol Microbiol (2006) 1.35
Wide dispersion of ST175 clone despite high genetic diversity of carbapenem-nonsusceptible Pseudomonas aeruginosa clinical strains in 16 Spanish hospitals. J Clin Microbiol (2011) 1.35
Physical activity and clinical and functional status in COPD. Chest (2009) 1.34
Nontypeable Haemophilus influenzae clearance by alveolar macrophages is impaired by exposure to cigarette smoke. Infect Immun (2009) 1.30
Inactivation of the hmgA gene of Pseudomonas aeruginosa leads to pyomelanin hyperproduction, stress resistance and increased persistence in chronic lung infection. Microbiology (2009) 1.29
Pseudomonas aeruginosa carbapenem resistance mechanisms in Spain: impact on the activity of imipenem, meropenem and doripenem. J Antimicrob Chemother (2011) 1.29
Characterization of the new metallo-beta-lactamase VIM-13 and its integron-borne gene from a Pseudomonas aeruginosa clinical isolate in Spain. Antimicrob Agents Chemother (2008) 1.29
Biological cost of hypermutation in Pseudomonas aeruginosa strains from patients with cystic fibrosis. Microbiology (2007) 1.20
Pan-β-lactam resistance development in Pseudomonas aeruginosa clinical strains: molecular mechanisms, penicillin-binding protein profiles, and binding affinities. Antimicrob Agents Chemother (2012) 1.19
Lack of association between hypermutation and antibiotic resistance development in Pseudomonas aeruginosa isolates from intensive care unit patients. Antimicrob Agents Chemother (2004) 1.18
Evaluation of the NCCLS extended-spectrum beta-lactamase confirmation methods for Escherichia coli with isolates collected during Project ICARE. J Clin Microbiol (2003) 1.17
Detection and susceptibility testing of hypermutable Pseudomonas aeruginosa strains with the Etest and disk diffusion. Antimicrob Agents Chemother (2004) 1.15
Alterations of OprD in carbapenem-intermediate and -susceptible strains of Pseudomonas aeruginosa isolated from patients with bacteremia in a Spanish multicenter study. Antimicrob Agents Chemother (2012) 1.13
Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. Antimicrob Agents Chemother (2009) 1.13
Affinity of the new cephalosporin CXA-101 to penicillin-binding proteins of Pseudomonas aeruginosa. Antimicrob Agents Chemother (2010) 1.13
Inactivation of the glycoside hydrolase NagZ attenuates antipseudomonal beta-lactam resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother (2009) 1.12
Risk factors and prognosis of nosocomial bloodstream infections caused by extended-spectrum-beta-lactamase-producing Escherichia coli. J Clin Microbiol (2010) 1.12
Inactivation of the mismatch repair system in Pseudomonas aeruginosa attenuates virulence but favors persistence of oropharyngeal colonization in cystic fibrosis mice. J Bacteriol (2007) 1.12
Environmental microbiota represents a natural reservoir for dissemination of clinically relevant metallo-beta-lactamases. Antimicrob Agents Chemother (2011) 1.11
Pseudomonas aeruginosa RsmA plays an important role during murine infection by influencing colonization, virulence, persistence, and pulmonary inflammation. Infect Immun (2007) 1.11
Providing β-lactams a helping hand: targeting the AmpC β-lactamase induction pathway. Future Microbiol (2011) 1.10
VIM-2-producing multidrug-resistant Pseudomonas aeruginosa ST175 clone, Spain. Emerg Infect Dis (2012) 1.09
Novel phosphorylcholine-containing protein of Pseudomonas aeruginosa chronic infection isolates interacts with airway epithelial cells. J Infect Dis (2008) 1.08
A large sustained endemic outbreak of multiresistant Pseudomonas aeruginosa: a new epidemiological scenario for nosocomial acquisition. BMC Infect Dis (2011) 1.07
NagZ inactivation prevents and reverts beta-lactam resistance, driven by AmpD and PBP 4 mutations, in Pseudomonas aeruginosa. Antimicrob Agents Chemother (2010) 1.06
Transferable multidrug resistance plasmid carrying cfr associated with tet(L), ant(4')-Ia, and dfrK genes from a clinical methicillin-resistant Staphylococcus aureus ST125 strain. Antimicrob Agents Chemother (2012) 1.04
High prevalence of undiagnosed airflow limitation in patients with cardiovascular disease. Chest (2009) 1.02
Antagonistic interactions of Pseudomonas aeruginosa antibiotic resistance mechanisms in planktonic but not biofilm growth. Antimicrob Agents Chemother (2011) 1.02
Biological markers of Pseudomonas aeruginosa epidemic high-risk clones. Antimicrob Agents Chemother (2013) 1.01
Prospective multicenter study of the impact of carbapenem resistance on mortality in Pseudomonas aeruginosa bloodstream infections. Antimicrob Agents Chemother (2011) 1.00
Molecular epidemiology and multidrug resistance mechanisms of Pseudomonas aeruginosa isolates from Bulgarian hospitals. Microb Drug Resist (2013) 1.00
Anti-biofilm and resistance suppression activities of CXA-101 against chronic respiratory infection phenotypes of Pseudomonas aeruginosa strain PAO1. J Antimicrob Chemother (2010) 1.00
Escherichia coli producing SHV-type extended-spectrum beta-lactamase is a significant cause of community-acquired infection. J Antimicrob Chemother (2009) 0.99
Differential beta-lactam resistance response driven by ampD or dacB (PBP4) inactivation in genetically diverse Pseudomonas aeruginosa strains. J Antimicrob Chemother (2010) 0.99
Intrinsic and environmental mutagenesis drive diversification and persistence of Pseudomonas aeruginosa in chronic lung infections. J Infect Dis (2011) 0.98
Expression of Toll-like receptor 2 is up-regulated in monocytes from patients with chronic obstructive pulmonary disease. Respir Res (2006) 0.97
ampG gene of Pseudomonas aeruginosa and its role in β-lactamase expression. Antimicrob Agents Chemother (2010) 0.97
Clonal dissemination, emergence of mutator lineages and antibiotic resistance evolution in Pseudomonas aeruginosa cystic fibrosis chronic lung infection. PLoS One (2013) 0.96
Effect of bronchial colonisation on airway and systemic inflammation in stable COPD. COPD (2012) 0.95
Colonisation and infection due to Enterobacteriaceae producing plasmid-mediated AmpC β-lactamases. J Infect (2011) 0.95
Genotype and phenotype at baseline and at failure in human immunodeficiency virus-infected antiretroviral-naive patients in a randomized trial comparing zidovudine and lamivudine plus nelfinavir or nevirapine. J Infect Dis (2003) 0.95
Assessing the emergence of resistance: the absence of biological cost in vivo may compromise fosfomycin treatments for P. aeruginosa infections. PLoS One (2010) 0.95
High β-lactamase levels change the pharmacodynamics of β-lactam antibiotics in Pseudomonas aeruginosa biofilms. Antimicrob Agents Chemother (2012) 0.95
Spanish multicenter study of the epidemiology and mechanisms of amoxicillin-clavulanate resistance in Escherichia coli. Antimicrob Agents Chemother (2012) 0.94
Chronic colonization by Pseudomonas aeruginosa of patients with obstructive lung diseases: cystic fibrosis, bronchiectasis, and chronic obstructive pulmonary disease. Diagn Microbiol Infect Dis (2010) 0.93
The effect of elevated mutation rates on the evolution of cooperation and virulence of Pseudomonas aeruginosa. Evolution (2009) 0.91
TEM-71, a novel plasmid-encoded, extended-spectrum beta-lactamase produced by a clinical isolate of Klebsiella pneumoniae. Antimicrob Agents Chemother (2002) 0.91
Dynamics of mutator and antibiotic-resistant populations in a pharmacokinetic/pharmacodynamic model of Pseudomonas aeruginosa biofilm treatment. Antimicrob Agents Chemother (2011) 0.90
AmpG inactivation restores susceptibility of pan-beta-lactam-resistant Pseudomonas aeruginosa clinical strains. Antimicrob Agents Chemother (2011) 0.90
Inappropriate use of antibiotics in hospitals: the complex relationship between antibiotic use and antimicrobial resistance. Enferm Infecc Microbiol Clin (2013) 0.89
Nontypable Haemophilus influenzae displays a prevalent surface structure molecular pattern in clinical isolates. PLoS One (2011) 0.88
Draft Genome Sequence of VIM-2-Producing Multidrug-Resistant Pseudomonas aeruginosa ST175, an Epidemic High-Risk Clone. Genome Announc (2013) 0.87
[Carbapenemases in Pseudomonas spp]. Enferm Infecc Microbiol Clin (2010) 0.87